Literature DB >> 17999093

Urinary annexin V in children with nephrotic syndrome: a new prognostic marker?

Behcet Simsek1, Mithat Buyukcelik, Mustafa Soran, Aysun K Bayazit, Aytul Noyan, Gulsah Seydaoglu, Ali Anarat.   

Abstract

Annexin V has a molecular weight of 32-35 kDa and has been reported to possess anticoagulant activity, inhibition of phospholipase A(2), regulation of membrane transport, proliferation and signal transduction. It is reported that urinary annexin V concentration may be an indicator of apoptosis and acute renal injury related to the urinary protein level. The aim of this study was to define the role of urinary annexin V excretion and serum annexin V concentrations as new prognostic tools and follow-up criteria in children with steroid-sensitive (SSNS) and steroid-resistant nephrotic syndrome (SRNS). Annexin V concentrations were measured in serum and 24-h urine samples in 23 SSNS patients in both relapse and remission periods of each patient and in 22 SRNS patients and 22 healthy controls. Total protein, albumin, blood urea nitrogen (BUN), creatinine, total cholesterol concentrations, and 24-h urinary excretion of protein and creatinine were also measured in each patient. In the SRNS group, median 24-h urinary annexin V levels were significantly higher than for all other groups (5,048.8 ng/g creatinine vs. 2,839.5 ng/g creatinine in SSNS relapse group; 2,500.0 ng/g creatinine in SSNS remission group, and 2,018.3 ng/g creatinine in healthy control group). No significant correlation was found between urinary protein excretion and 24-h urinary annexin V levels in all subjects. Twenty-four-hour urinary annexin V excretion may be a predictor in children with SRNS, and it may be a prognostic marker in children with NS.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17999093     DOI: 10.1007/s00467-007-0606-z

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  9 in total

1.  Localization of annexin V in rat normal kidney and experimental glomerulonephritis.

Authors:  R Matsuda; N Kaneko; Y Horikawa; F Chiwaki; M Shinozaki; T Ieiri; T Suzuki; N Ogawa
Journal:  Res Exp Med (Berl)       Date:  2001-01

2.  Inhibition of annexin V-dependent Ca2+ movement in large unilamellar vesicles by K201, a new 1,4-benzothiazepine derivative.

Authors:  N Kaneko; R Matsuda; M Toda; K Shimamoto
Journal:  Biochim Biophys Acta       Date:  1997-11-13

3.  Measurement of urinary annexin V by ELISA and its significance as a new urinary-marker of kidney disease.

Authors:  R Matsuda; N Kaneko; Y Horikawa; F Chiwaki; M Shinozaki; S Abe; W Yumura; H Nihei; T Ieiri
Journal:  Clin Chim Acta       Date:  2000-08       Impact factor: 3.786

4.  Increased apoptosis of peripheral blood lymphocytes in children with nephrotic syndrome.

Authors:  Jacek Zachwieja; Grzegorz Dworacki; Waldemar Bobkowski; Agnieszka Dobrowolska-Zachwieja; Marcin Zaniew; Janusz Maciejewski
Journal:  Pediatr Nephrol       Date:  2002-03       Impact factor: 3.714

5.  Measurement of plasma annexin V by ELISA in the early detection of acute myocardial infarction.

Authors:  N Kaneko; R Matsuda; S Hosoda; T Kajita; Y Ohta
Journal:  Clin Chim Acta       Date:  1996-07-15       Impact factor: 3.786

6.  Clinical significance of measurement of plasma annexin V concentration of patients in the emergency room.

Authors:  Ryuko Matsuda; Noboru Kaneko; Migaku Kikuchi; Fumiko Chiwaki; Masashi Toda; Tamio Ieiri; Yoshifumi Horikawa; Mayumi Shimizu; Ken Shimamoto
Journal:  Resuscitation       Date:  2003-05       Impact factor: 5.262

Review 7.  The role of apoptosis in autoimmunity: immunogen, antigen, and accelerant.

Authors:  J S Levine; J S Koh
Journal:  Semin Nephrol       Date:  1999-01       Impact factor: 5.299

8.  Altered in vitro lymphocyte response in childhood nephrotic syndrome.

Authors:  I K Hewitt; A K House; J M Potter; B F Kinnear
Journal:  Pediatr Nephrol       Date:  1992-09       Impact factor: 3.714

9.  Structural and functional characterisation of the voltage sensor in the ion channel human annexin V.

Authors:  S Liemann; J Benz; A Burger; D Voges; A Hofmann; R Huber; P Göttig
Journal:  J Mol Biol       Date:  1996-05-17       Impact factor: 5.469

  9 in total
  5 in total

1.  Role of annexin A5 in cisplatin-induced toxicity in renal cells: molecular mechanism of apoptosis.

Authors:  Jin-Joo Jeong; Nahee Park; Yeo-Jung Kwon; Dong-Jin Ye; Aree Moon; Young-Jin Chun
Journal:  J Biol Chem       Date:  2013-12-06       Impact factor: 5.157

2.  Sitagliptin exerts anti-apoptotic effect in nephrotoxicity induced by cisplatin in rats.

Authors:  Rehab S Abdelrahman
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2017-04-05       Impact factor: 3.000

3.  Genomic, Proteomic, and Phenotypic Spectrum of Novel O-Sialoglycoprotein Endopeptidase Variant in Four Affected Individuals With Galloway-Mowat Syndrome.

Authors:  Malak Ali Alghamdi; Hicham Benabdelkamel; Afshan Masood; Narjes Saheb Sharif-Askari; Mahmood Y Hachim; Hamad Alsheikh; Muddathir H Hamad; Mustafa A Salih; Fahad A Bashiri; Khalid Alhasan; Tarek Kashour; Pilar Guatibonza Moreno; Sabine Schröder; Vasiliki Karageorgou; Aida M Bertoli-Avella; Hisham Alkhalidi; Dima Z Jamjoom; Ibrahim A Alorainy; Assim A Alfadda; Rabih Halwani
Journal:  Front Genet       Date:  2022-06-23       Impact factor: 4.772

4.  Annexin A5 suppresses cyclooxygenase-2 expression by downregulating the protein kinase C-ζ-nuclear factor-κB signaling pathway in prostate cancer cells.

Authors:  Hyoung-Seok Baek; Nahee Park; Yeo-Jung Kwon; Dong-Jin Ye; Sangyun Shin; Young-Jin Chun
Journal:  Oncotarget       Date:  2017-07-19

5.  Annexin A5 prevents amyloid-β-induced toxicity in choroid plexus: implication for Alzheimer's disease.

Authors:  Fernando Bartolome; Agnieszka Krzyzanowska; Macarena de la Cueva; Consuelo Pascual; Desiree Antequera; Carlos Spuch; Alberto Villarejo-Galende; Alberto Rabano; Juan Fortea; Daniel Alcolea; Alberto Lleo; Isidro Ferrer; John Hardy; Andrey Y Abramov; Eva Carro
Journal:  Sci Rep       Date:  2020-06-10       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.